Pharma & Bio
Lifestyle
WSI Co., Ltd. Brings Medical Robotics and New Drug Industries into Focus… Setting Its Sights on the “100 Billion Club” by 2028
WSI Co., Ltd.(299170), a company specializing in pharmaceuticals and medical devices, is breaking away from its long-standing distribution-centric business model—which had been heavily reliant on a si…
- 2026-09-08 08:41:03
- YU JIN-HEE
Technology
CureStream Aims for ‘AI Pancreas Subscription’ Beyond Insulin Pumps… Targeting an IPO in 2028
CureStream, a developer of insulin pumps, has received approval for its AI-based, fully autonomous insulin delivery algorithm as an independent software medical device and is launching a subscription …
- 2026-09-08 07:27:03
- NA EUN-KYUNG
Business·Industry
[Noul Co., Ltd. Deep Seek ②] Mergers of Penny Stocks Are Not the End… 'Triple-Tiered Watch List Risk'
Noul Co., Ltd.(376930)Although the company is proceeding with a 5-to-1 stock consolidation following its designation as a “monitored stock” due to a share price below 1,000 won, the risk of delisting …
- 2026-09-07 08:31:02
- KIM SAE-MI
Lifestyle
Mezzion Pharma Co., Ltd. Launches Udenafil Clinical Trials in the U.K. Following Korea and the U.S. … Final Piece of the Puzzle in Place for Fontan Treatment Approval
Mezzion Pharma Co., Ltd.(140410)is expanding the scope of “FUEL-2,” the global Phase 3 clinical trial for udenafil—a drug under development for the treatment of Fontan patients—to the United Kingdom. …
- 2026-09-07 08:26:01
- KIM JI-WAN
Technology
GSK Also Bets Up to $1.4 Billion on a New Drug from China… K-Bio Falls Further Behind China
(Graphic: ChatGPT)
GlaxoSmithKline (GSK) is set to begin full-scale Phase 3 clinical trials for a long-acting antibody called “felcorekibart,” which originated in China. This comes approximately t…
- 2026-09-07 08:01:03
- Minji Son
Technology
i-SENS, Inc., Once a Money Pit, Takes Off… With Margins in the Mid-40s, Can It Achieve Annual Sales of 40 Billion?
i-SENS, Inc.(099190)’s continuous glucose monitoring (CGM) business has begun to secure profitability following its revenue growth. With CGM sales in the first half of this year surpassing last year’s…
- 2026-09-07 08:01:02
- NA EUN-KYUNG
Lifestyle
Skylabs Makes a Strong Debut; Samik Pharma and Penetrium Bio Also Surge [K-Bio Pulse]
As the domestic stock market refocuses on solid corporate performance, clinical developments, and tangible commercialization milestones, the biotech sector saw strong capital inflows on September 4, t…
- 2026-09-07 07:51:04
- YU JIN-HEE
Lifestyle
SkyLabs Makes Its Mark on First Day of Listing… SAMIK PHARM. Co., LTD. and PenetriumBio Also Rise [Bio Spotlight]
As the domestic securities market has recently been realigning itself around corporate earnings and tangible clinical and commercialization achievements, the biotech sector also saw strong buying inte…
- 2026-09-07 07:51:03
- YU JIN-HEE
Lifestyle
“Expanding into the Aesthetics Market… Establishing a 90 Billion Won Production System”
“Building on the solid manufacturing infrastructure established through oral care over-the-counter products and the reputation for quality accumulated over the past 20 years, we are now actively expan…
- 2026-09-06 08:27:02
- YU JIN-HEE
Technology
GC Wellbeing and JW Pharmaceutical Rally [K-bio Pulse]
South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology. #GCWellbeing sur…
- 2026-09-05 08:02:02
- Kim Seung-kwon
PHARM EDAILY
Shorts